research: tivozanib, new VEGF inhibitor in clinical trials

A drug in Phase I clinical trials is showing good results in treatment for metastatic breast cancer when combined with paclitaxel. AVEO Pharmaceutical Company’s tivozanib is a selective VEGF receptor inhibitor. Dr. Erica L. Mayer, medical oncologist at the Breast Oncology Center, Dana-Farber Institute, presented a poster session indicating positive results for tivozanib, combined with Taxol®, including progression-free survival. Since Phase I demonstrated safety for doses up to full dosage, we should be watching for announcements of Phase II studies. Additionally, Phase I clinical trials of tivozanib have reported no severe side effects.

One wonders if this could be the next drug of promise to fill the gap left by the exit of Avastin®.

Time for more reading and talking to our oncologists.

AVEO’s Tivozanib In Combination With Paclitaxel Demonstrates Safety In Patients With Metastatic Breast Cancer. Medical News Today 12/17/10

5 6 7 8
© 2004–2010 Donna Peach. All rights reserved.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s